Global CAR T-Cell Therapy Market Growth (Status and Outlook) 2025-2031

Global CAR T-Cell Therapy Market Growth (Status and Outlook) 2025-2031

The global CAR T-Cell Therapy market size is predicted to grow from US$ 5299 million in 2025 to US$ 22200 million in 2031; it is expected to grow at a CAGR of 27.0% from 2025 to 2031.

CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative form of immunotherapy that involves genetically modifying a patient’s own T cells to express a specific chimeric antigen receptor (CAR) on their surface. This receptor enables the T cells to target and destroy cancer cells effectively. CAR-T therapy has shown significant success in treating hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphomas, and is being explored for its potential applications in solid tumors.

The CAR-T Cell Therapy market is primarily driven by its groundbreaking effectiveness in treating certain types of hematological malignancies, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), particularly in patients who are refractory to standard treatments. The rising incidence of cancer globally and the growing demand for personalized and targeted therapies have further fueled market growth. In addition, advancements in genetic engineering and manufacturing processes are making CAR-T therapies safer, more efficient, and increasingly accessible. The strong support from government initiatives and private investments in oncology research is also accelerating the development of next-generation CAR-T products, expanding their therapeutic potential to include solid tumors.However, the market faces significant challenges, including the high cost of CAR-T therapies, which can exceed hundreds of thousands of dollars per treatment, making it inaccessible to many patients. The complex and time-consuming manufacturing process, which involves extracting and engineering a patient’s T cells, further contributes to these high costs. Additionally, CAR-T therapy is associated with severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, which require specialized management and can limit its broader adoption. Regulatory hurdles and the need for improved scalability also present obstacles, particularly in developing regions where healthcare infrastructure may be inadequate to support this advanced therapy.

The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.

LPI (LP Information)' newest research report, the “CAR T-Cell Therapy Industry Forecast” looks at past sales and reviews total world CAR T-Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Therapy sales for 2025 through 2031. With CAR T-Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global CAR T-Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR T-Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR T-Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
CD19 - Targeted
BCMA - Targeted

Segmentation by Application:
Lymphoma
Multiple Myeloma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)

Please note: The report will take approximately 2 business days to prepare and deliver.